• 제목/요약/키워드: HLA-B antigens

검색결과 11건 처리시간 0.022초

한국형 출혈열 및 만성간염과 조직적합성 항원간의 유전적 관련성에 관한 연구(II) -(II) 만성간염과 조직적합성 항원간의 유전적 관련성에 관한 연구- (Study on the Genetic Relationship between Korean Hemorrhagic Fever, Chronic Hepatitis and Histocompatibility Antigens(II) -(II) Study on the Genetic Relationship between Chronic Hepatitis and Histocompatibility Antigens-)

  • 한훈;김태규;유문간;임병욱;김금용;이종훈;김부성;김호연;윤영석;방병기;민병석;김한화;박희봉
    • 대한미생물학회지
    • /
    • 제21권2호
    • /
    • pp.233-241
    • /
    • 1986
  • Patients of chronic hepatic diseases(n=107) including chronic hepatitis caused by hepatitis B virus infections(n=31), liver cirrhosis(n=53), and hepatocellular carcinoma(n=23) were examined to ascertain genetic relationship between chronic hepatic diseases and histocompatibility antigen. Peripheral blood lymphocytes were separated from whole blood by the method of Ficoll/Hypaque gradient. Total 54 histocompatibility antigens(class I antigens: 41, class II antigens: 13) were analysed by performing of complement dependent microlymphocytotoxicity method using Terasaki's and Catholic Medical College tissue typing plates. HLA antigen frequencies were compared with those of 661 normal controls. The following results were obtained: 1. HLA antigen frequencies of HLA-Bw46, -Bw76, -Cw1, -Cw6, and HLA-DR8 in chronic hepatitis patients were shown to be higher than those in controls(P<0.01). 2. HLA antigen frequencies of HLA-Bw46, -Cw7(P<0.01), and HLA-B37, -Bw58, -Cw1, -MT1(P < 0.05) in liver cirrhosis patients were shown relatively higher frequencies than those in controls. 3. In patients with hepatocellular carcinoma, antigens of HLA-A1, -A26, -Cw3, -Cw7 and HLA-DR6 were dominantly detected. 4. There were negative associations with HLA-Cw4, and -DR4 in patients of chronic hepatic diseases(P < 0.05).

  • PDF

Molecular Analysis of HLA-C Using Polymerase Chain Reaction-Sequence Specific Primers

  • Lee, Kyung-Ok;Hong, Sung-Hoi;Kim, Min-Jung;Park, Taek-Kyu;Kim, Yoon-Jung;Lee, Kyu-Pum
    • BMB Reports
    • /
    • 제30권1호
    • /
    • pp.26-32
    • /
    • 1997
  • Of all HLA class I molecules, HLA-C gene products are most poorly understood because they express at a low level on the cell surface compared to HLA-A and -B. In order to identify serologically detectable and undetectable HLA-C antigens, we have established a DNA-based tissue typing method for the HLA-C locus by PCR-SSP (polymerase chain reaction-sequence specific primers). Genomic DNA prepared from Iymphoblastoid 21 B-cell lines and 120 Korean individuals by proteinase K digestion and pheno/chloroform extractions have been typed by PCR-SSP (23 primer mixes were used). The PCR-SSP results of control cell lines were discrepant from serology in 1 case among 21 cases: Cw6 which was negative by serology but positive by PCR-SSP (cell line: MANIKA). Twenty four HLA-Cw "blank" antigens among fifty Korean individuals were completely determined by PCR-SSP DNA typing. HLA-Cw*0101 (15.3%), Cw*1401 (12.3%) and Cw*0701 (11.7%) alleles were frequently found in 120 Korean individual samples. In conclusion. the high level of discrimination for HLA-C alleles may prove useful and informative in the study of transplant survival, and identify the importance of allelic differences, not readily detectable by serology, on host and donor compatibility.

  • PDF

HLA-A, HLA-B, HLA-DRB1 Polymorphisms and Risk of Cervical Squamous Epithelial Cell Carcinoma: A Population Study in China

  • Xiao, Xue;Liu, Li;Li, Wei-Jie;Liu, Juan;Chen, Dun-Jin
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권7호
    • /
    • pp.4427-4433
    • /
    • 2013
  • Cervical cancer is the second most common cancer in women. HLA class I and II alleles polymorphisms have been shown to be associated with cervical cancer risk, but results have varied among different populations. In this study, the HLA-A, -B, and -DRB1 alleles among 100 southern Chinese women with cervical squamous cell carcinoma (SCC) were compared to 254 controls. Our results showed that $B^*51$:01:02 allele frequency was significantly higher in patients with SCC than in healthy controls ($P=3.17{\times}10^{-5}$, $P_c$=0.005, OR=26.7). Statistical analysis also revealed a significantly decreased frequency of $B^*51$:01:02 ($P=7.01{\times}10^{-4}$, $P_c$=0.03, OR=0.12) in patients with SCC when compared with healthy controls. These results indicate that HLA-$B^*51$:01:02 may confer susceptibility to SCC and HLA-$B^*51$:01:02 may contribute to resistance to the development of SCC in Chinese women. None of the HLA-A-B or HLA-A-B-DRB1 haplotypes were significantly different in cases and controls after multiple testing corrections, indicating the individual allele associations to be independent of the identified haplotypes. These results support the hypothesis that some HLA-B alleles could be involved with susceptibility for developing SCC.

Cross-immunizing potential of tumor MAGE-A epitopes recognized by HLA-A*02:01-restricted cytotoxic T lymphocytes

  • Huang, Ze-Min;Jia, Zheng-Cai;Tang, Jun;Zhang, Yi;Tian, Yi;Ni, Dong-Jing;Wang, Fang;Wu, Yu-Zhang;Ni, Bing
    • BMB Reports
    • /
    • 제45권7호
    • /
    • pp.408-413
    • /
    • 2012
  • Almost all melanoma cells express at least one member of the MAGE-A antigen family, making the cytotoxic T cells (CTLs) epitopes with cross-immunizing potential in this family attractive candidates for the broad spectrum of anti-melanoma immunotherapy. In this study, four highly homologous peptides (P264: FLWGPRALA, P264I9: FLWGPRALI, P264V9: FLWGPRALV, and P264H8: FLWGPRAHA) from the MAGE-A antigens were selected by homologous alignment. All four peptides showed high binding affinity and stability to HLA-A$^*02:01$ molecules, and could prime CTL immune responses in human PBMCs and in HLA-A$^*02:01/K^b$ transgenic mice. CTLs elicited by the four epitope peptides could cross-lyse tumor cells expressing the mutual target antigens, except MAGE-A11 which was not tested. However, CTLs induced by P264V9 and P264I9 showed the strongest target cell lysis capabilities, suggesting both peptides may represent the common CTL epitopes shared by the eight MAGE-A antigens, which could induce more potent and broad-spectrum antitumor responses in immunotherapy.

폐쇄성 수면무호흡증후군 환자에서 사람백혈구항원 분석 (Analysis of HLA in Patients with Obstructive Sleep Apnea Syndrome)

  • 이상학;김치홍;안중현;강지호;김관형;송정섭;박성학;문화식;최희백;김태규;최영미
    • Tuberculosis and Respiratory Diseases
    • /
    • 제59권3호
    • /
    • pp.298-305
    • /
    • 2005
  • 연구배경 : 폐쇄성 수면무호흡증후군은 다양한 원인에 의해 발생하게 된다. 주된 위험요소로는 비만과 좁은 상기도, 비정상적인 머리-얼굴 구조 등이 알려져 있으며 유전적 요인 또한 가족내 집단적 발생하였다는 보고들에 의해 뒷받침되고 있다. 본 연구에서 저자들은 HLA검사를 통하여 폐쇄성 수면무호흡증후군에서 유전학적인 배경을 규명하고자 하였다. 방 법 : 철야 수면다원검사로 진단한 25명의 폐쇄성 수면무호흡증후군 환자 (여자 1명과 남자 24명, 연령 30-66세)를 대상으로 하였으며 대조군은 200명의 건강한 한국인으로 하였다. HLA-A와 -B 대립유전자의 검사는 미세세포독성검사로 시행하였고 HLA-DRB1 유전자의 두번째 엑손의 다형성에 대한 분석은 PCRSSOP방법을 이용하여 시행하였다. 결 과 : HLA-A11 대립유전자의 빈도는 폐쇄성 수면무호흡증후군 환자군에서 대조군에 비해 유의하게 감소되어 있었다 (p<0.05). HLA-B 대립유전자의 빈도는 양군간에 유의한 차이가 없었다. HLA-DRB1 유전자의 다형태 분석에서는 DRB1*09의 빈도가 폐쇄성 수면무호흡환자군에서 대조군에 비해 유의하게 증가되어 있었다 (p <0.05). 환자군을 무호흡지수 45를 기준으로 경-중등증군과 중증군으로 나누어 대조군과 비교하였을 때 중증군에서 HLA-DRB1*08의 빈도가 유의하게 증가되어 있었다 (p <0.05). 결 론 : 한국의 폐쇄성 수면무호흡증후군 환자에서 HLAA11과 DRB1*09가 폐쇄성 수면무호흡증후군과 관련되어 있고, HLA-DRB1*08이 이 질환의 중증도와 연관되어 있음을 알 수 있었다. 이상의 결과는 폐쇄성 수면 무호흡 증후군의 발생뿐 아니라 경중도 여부에도 유전적인 요소가 중요한 역할을 한다는 것을 시사한다.

여자 전신성 홍반성 낭창 환자에서 발생한 천장골염 1례 (Symptomatic Sacroiliitis in Female Systemic Lupus Erythematosus)

  • 박기도;홍영훈;김성동;류동환;이충기
    • Journal of Yeungnam Medical Science
    • /
    • 제17권2호
    • /
    • pp.161-164
    • /
    • 2000
  • 저자들은 17세 여자환자로 심한 전신성 홍반성 낭창과 동반되어 발생한 유증상의 천장골염을 보고한다. 이 환자는 HLA B27이나 DR3와 연관성이 없이 천장골염이 발생하였으며, 남자 전신성 홍반성 낭창 환자에서는 종종 천장골염이 보고된바는 있으나 여자환자에서 천장골염이 보고된 경우는 드물어 보고하며, 저자들의 견해로는 전신성 홍반성 낭창에서 천장골염의 동반은 희귀한 유전학적 표시자의 조합만으로 설명하기 힘들며 드문 전신성 홍반성 낭창의 임상양상으로 추정된다.

  • PDF

Active Immunization Study of Colon Cancer Derived 1-8D Peptide in HHD Mice

  • Jung, Hun-Soon;Ahn, In-Sook;Do, Hyung-Ki;Lemonnier, Francois A.;Song, Kuk-Hyun;Do, Myoung-Sool
    • IMMUNE NETWORK
    • /
    • 제5권3호
    • /
    • pp.157-162
    • /
    • 2005
  • Background: 1-8D gene is a member of human 1-8 interferon inducible gene family and was shown to be overexpressed in fresh colon cancer tissues. Three peptides 1-6, 3-5 and 3-7 derived from human 1-8D gene were shown to have immunogenicity against colon cancer. Methods: To study tumor immunotherapy, of three peptides we established an active immunization model using HHD mice. $D^{b-/-}{\times}{\beta}2$ microglobulin $({\beta}2m)$ null mice transgenic for a chimeric HLA-$A2.1/D^{b-}\;{\beta}2m$ single chain (HHD mice) were challenged with B16/HHD/1-8D tumor cells and were immunized with irradiated peptide-loaded RMA- S/HHD/B7.1 transfectants. In therapy model tumor growth was retarded in HHD mice that were injected with 3-5 peptide-loaded RMA-S/HHD/B7.1. In survival test vaccination with 1-8D-derived peptide protects HHD mice from tumor progression after tumor challenge. Results: These studies show that peptide 3-5 derived from 1-8D gene can be the most effective candidate for the vaccine of immunotherapy against colon cancer and highlight 1-8D gene as putative colon carcinoma associated antigens. Conclusion: We demonstrated that RMA-S/HHD/ B7.1 loaded with 1-8D peptides, especially 3-5, immunization generates potent antitumor immunity against tumor cells in HHD mice and designed active immunization as proper immunotherapeutic protocols.

Mycobacterium tuberculosis Derived Epitope Peptide Specific CD8+T Cell Responses in Tuberculous Pleurisy

  • ;;;;;조상래;조성애
    • 대한의생명과학회지
    • /
    • 제13권4호
    • /
    • pp.325-332
    • /
    • 2007
  • Cell-mediated immune response (CMI) is a major immune protective mechanism against tuberculosis (TB) infection. Among several components involved in CMI, recent studies suggest that CD8+ T cells are important in controlling TB infection. In our previous report, we defined four Mycobacterium tuberculosis (MTB) derived epiotpe peptides specific for HLA-A*0201-restricted CD8+ T cells. These four peptides are $PstAl_{75-83}$, $ThyA_{30-38}$, $RpoB_{127-135}$ and $85B_{15-23}$. In this study, these epitope peptides specific CD8+ T cell responses in tuberculous pleurisy were investigated using ex vivo $IFN-\gamma$ elispot assay and intracellular $IFN-\gamma$ staining method. As a result, we observed these epitope peptide specific CD8+ T cell responses are induced in all three patients with tuberculous pleurisy suggesting that CD8+ T cells are involved in protective immune mechanism against MTB infection in tuberculous pleurisy. However, the CMI to mitogens and MTB antigens from pleural fluids of patients with tuberculous pleurisy does not seem to correlate with that from peripheral blood, although the sample size is too small to make any conclusion. In sum, the MHC I restricted CD8+ T cell responses seem to be induced efficiently in the pleural fluids, at the site of TB infection, in which the CMI is actively induced. In addition, these experiments suggest that MHC I restricted CD8+ T cell mediated immune responses are also involved in protective mechanism against MTB infection in extra-pulmonary TB.

  • PDF

Donor Specific Antibody Negative Antibody-Mediated Rejection after ABO Incompatible Liver Transplantation

  • Lee, Boram;Ahn, Soomin;Kim, Haeryoung;Han, Ho-Seong;Yoon, Yoo-Seok;Cho, Jai Young;Choi, Young Rok
    • 대한이식학회지
    • /
    • 제32권4호
    • /
    • pp.108-112
    • /
    • 2018
  • Antibody-mediated rejection (AMR) is a major complication after ABO-incompatible liver transplantation. According to the 2016 Banff Working Group on Liver Allograft Criteria for the diagnosis of acute AMR, a positive serum donor specific antibody (DSA) is needed. On the other hand, the clinical significance of the histological findings of AMR in the absence of DSA is unclear. This paper describes a 57-year-old man (blood type, O+) who suffered from hepatitis B virus cirrhosis with hepatocellular carcinoma. Pre-operative DSA and cross-matching were negative. After transplantation, despite the improvement of the liver function, acute AMR was observed in the protocol biopsy on postoperative day 7; the cluster of differentiation 19+ (CD19+) count was 0% and anti-ABO antibody titers were 1:2. This paper presents the allograft injury like AMR in the absence of DSA after ABOi living donor liver transplantation with low titers of anti-ABO antibody and depleted serum CD19+ B cells.

Alternative Splicing of Breast Cancer Associated Gene BRCA1 from Breast Cancer Cell Line

  • Lixia, Miao;Zhijian, Cao;Chao, Shen;Chaojiang, Gu;Congyi, Zheng
    • BMB Reports
    • /
    • 제40권1호
    • /
    • pp.15-21
    • /
    • 2007
  • Breast cancer is the most common malignancy among women, and mutations in the BRCA1 gene produce increased susceptibility to these malignancies in certain families. In this study, the forward 1-13 exons of breast cancer associated gene BRCA1 were cloned from breast cancer cell line ZR-75-30 by RT-PCR method. Sequence analysis showed that nine BRCA1 splice forms were isolated and characterized, compared with wild-type BRCA1 gene, five splice forms of which were novel. These splice isoforms were produced from the molecular mechanism of 5' and 3' alternative splicing. All these splice forms deleting exon 11b and the locations of alternative splicing were focused on two parts:one was exons 2 and 3, and the other was exons 9 and 10. These splice forms accorded with GT-AG rule. Most these BRCA1 splice variants still kept the original reading frame. Western blot analysis indicated that some BRCA1 splice variants were expressed in ZR-75-30 cell line at the protein level. In addition, we confirmed the presence of these new transcripts of BRCA1 gene in MDA-MB-435S, K562, Hela, HLA, HIC, H9, Jurkat and human fetus samples by RT-PCR analysis. These results suggested that breast cancer associated gene BRCA1 may have unexpectedly a large number of splice variants. We hypothesized that alternative splicing of BRCA1 possibly plays a major role in the tumorigenesis of breast and/or ovarian cancer. Thus, the identification of cancer-specific splice forms will provide a novel source for the discovery of diagnostic or prognostic biomarkers and tumor antigens suitable as targets for therapeutic intervention.